证券代码：300142 证券简称：沃森生物 公告编号：2025-067 云南沃森生物技术股份有限公司 第五届董事会第三十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 云南沃森生物技术股份有限公司（以下简称"公司"）第五届董事会第三十 三次会议于 2025 年 11 月 28 日以通讯表决的方式召开，会议通知于 11 月 24 日 以电子邮件方式发出。本次会议应参会董事 10 人，实际参加会议董事 10 人。会 议由董事长李云春先生主持。本次会议的召集、召开符合《公司法》等法律法规、 部门规章、规范性文件及《公司章程》的规定。 二、董事会会议审议情况 1、审议通过了《关于聘请公司 2025 年度审计机构的议案》 大信会计师事务所（特殊普通合伙）具备从事证券、期货相关业务的资格， 具有为上市公司提供年度审计的经验和能力，在对公司 2024 年度财务报告和内 部控制进行审计的过程中，坚持独立、客观、公正的审计原则，公允合理地发表 了独立审计意见，具备足够的独立性、专业胜任能力和投资者保护能力。董事会 同意公司聘请大信会计师 ...

证券代码：300142 证券简称：沃森生物 公告编号：2025-072 一、交易背景及概述 1、交易的基本情况 公司控股子公司玉溪沃森生物技术有限公司（以下简称"玉溪沃森"或"目 标公司"）少数股东天津蓝沃投资合伙企业（有限合伙）（以下简称"天津蓝沃" 或"转让方"）拟转让其所持有的玉溪沃森 2.4793%股权，鉴于玉溪沃森为公司 重要的核心子公司，经综合考虑玉溪沃森的实际情况及公司未来长远发展规划， 董事会同意公司受让本次天津蓝沃拟转让的玉溪沃森 2.4793%股权（对应玉溪沃 森注册资本人民币 3,439.588 万元），股权转让价格为人民币 35,949.85 万元，并 与天津蓝沃签署《玉溪沃森生物技术有限公司之股权转让协议》（以下简称《股 权转让协议》）。 2、董事会表决情况 公司第五届董事会第三十三次会议审议通过《关于受让控股子公司少数股权 并与天津蓝沃投资合伙企业（有限合伙）签署<股权转让协议>的议案》。本次 受让玉溪沃森 2.4793%股权并与天津蓝沃签署《股权转让协议》属于董事会审议 权限范围，无需提交公司股东大会审议。 云南沃森生物技术股份有限公司 关于受让控股子公司少数股权并与天津蓝沃投资 ...

证券代码：300142 证券简称：沃森生物 公告编号：2025-071 云南沃森生物技术股份有限公司 关于受让控股子公司少数股权并与汇祥越泰（天津）投资合伙企 业（有限合伙）签署《股权转让协议》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 云南沃森生物技术股份有限公司（以下简称"公司"或"受让方"）于 2025 年 11 月 28 日召开第五届董事会第三十三次会议，审议通过了《关于受让控股子 公司少数股权并与汇祥越泰（天津）投资合伙企业（有限合伙）签署<股权转让 协议>的议案》。现将相关情况公告如下： 一、交易背景及概述 1、交易的基本情况 公司控股子公司玉溪沃森生物技术有限公司（以下简称"玉溪沃森"或"目 标公司"）少数股东汇祥越泰（天津）投资合伙企业（有限合伙）（以下简称"汇 祥越泰"或"转让方"）拟转让其所持有的玉溪沃森 11.3043%股权，鉴于玉溪 沃森为公司重要的核心子公司，经综合考虑玉溪沃森的实际情况及公司未来长远 发展规划，董事会同意公司受让本次汇祥越泰拟转让的玉溪沃森 11.3043%股权 （对应玉溪沃森注册资本人民币 15,683 ...

大信审字[2025]第 5-00383 号 大信会计师事务所（特殊普通合伙） 玉溪沃森生物技术有限公司 审 计 报 告 审 计 报 告 大信审字[2025]第 5-00383 号 玉溪沃森生物技术有限公司： 一、审计意见 我们审计了玉溪沃森生物技术有限公司（以下简称"贵公司 "）的财务报表，包括 2025 年 6 月 30 日的资产负债表，2025 年 1-6 月的利润表、现金流量表、所有者权益变动表，以及 财务报表附注。 WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 邮编 100083 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 WUYIGE Certified Public Accountants.LLP Room 2206 22/F,Xueyuan International Tower No. 1 Zhichun Road, Haidian Dist. Beijing,China,100083 电话 Telephone： +86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： ww ...

Core Viewpoint - Watson Bio announced the acquisition of a 2.4793% stake in its subsidiary Yuxi Watson from Tianjin Lanwo for a price of 359.4985 million yuan, which is expected to enhance control over Yuxi Watson and positively impact the company's performance for the current year, although there are uncertainties involved [1] Financial Summary - Yuxi Watson's projected revenue for 2024 is 2.664 billion yuan and net profit is 254 million yuan [1] - For the first nine months of 2025, Yuxi Watson reported revenue of 1.682 billion yuan and net profit of 269 million yuan [1] Transaction Details - The board meeting for the acquisition is scheduled for November 28, 2025, with payment due by November 30, 2025, and formal transfer of shares upon completion of business registration [1]

Core Viewpoint - Watson Bio has received a marketing authorization for its 13-valent pneumococcal polysaccharide conjugate vaccine from the Egyptian Drug Authority, marking a significant step in its international expansion efforts [1] Group 1: Company Developments - Watson Bio's vaccine products have been exported to over 24 countries and regions, with a total export volume exceeding 63 million doses [3] - The company has successfully entered new markets including Chile and Jordan for its 13-valent pneumococcal conjugate vaccine, and has also expanded its 23-valent pneumococcal polysaccharide vaccine to Chile, Mexico, and El Salvador [2] - Watson Bio has completed a localization project in Indonesia, beginning to export raw materials to local partners [2] Group 2: Industry Trends - Multiple vaccine companies are accelerating their global strategies, with significant partnerships and contracts being established, such as Beijing Kexing's $700 million deal with Brazil [2] - The overseas sales revenue of several vaccine companies has shown substantial growth, with Chengda Bio achieving a 26.96% increase and Wantai Bio seeing a 77.51% increase in overseas sales [3] - The vaccine industry is transitioning from scale expansion to innovation-driven growth, with supply-demand imbalances and homogenized competition posing short-term challenges, but long-term growth prospects remain positive [3]

（文章来源：证券日报） 证券日报网讯沃森生物11月27日在互动平台回答投资者提问时表示，公司按照相关法规和规范性文件的 规定在各期定期报告中披露报告期末的股东人数。 ...

Core Insights - The price war in the vaccine industry is driven by changes in supply and demand dynamics, leading to significant price reductions and financial losses for companies [2][10][15] Group 1: Price Trends - The price of a three-valent flu vaccine has dropped to 5.5 yuan, lower than the price of a cup of milk tea, indicating a drastic reduction in vaccine prices [3][7] - The price of the four-valent flu vaccine has decreased from 128 yuan to 88 yuan, with further reductions expected as competition intensifies [7][8] - HPV vaccines have also seen significant price drops, with the two-valent HPV vaccine priced at 27.5 yuan, down over 90% from previous prices [8] Group 2: Industry Response - The China Vaccine Industry Association issued an initiative to combat "involutionary" competition, urging members to avoid bidding below cost and maintain price stability [4][5] - The association's initiative aims to stabilize price expectations but may not address the underlying issue of overcapacity in the industry [3][10] Group 3: Market Dynamics - The vaccine market is experiencing overcapacity due to an influx of companies entering the sector, leading to intense competition and price wars [10][11] - Demand for vaccines is under pressure, with declining public trust in vaccines and a decrease in birth rates affecting the market for childhood vaccines [11][12] Group 4: Financial Impact - Vaccine companies have reported significant financial losses, with overall revenue for listed vaccine companies dropping by 60% and net profits declining by 113% in the first half of 2025 [12][14] - Major companies like Zhifei Biological and Wantai Biological have reported substantial revenue declines and net losses, reflecting the severe impact of the price war [12][14] Group 5: Future Outlook - Experts suggest that the industry may need to undergo a period of consolidation and restructuring, which could last five to ten years, to address the current challenges [15] - Companies are exploring international markets and differentiation strategies to navigate the competitive landscape, with some reporting significant increases in exports [15]

（编辑 姚尧） 证券日报网讯 11月26日晚间，沃森生物发布公告称，云南沃森生物技术股份有限公司（以下简称"公 司"）子公司玉溪沃森生物技术有限公司生产的13价肺炎球菌多糖结合疫苗（以下简称"13价肺炎结合疫 苗"）于近日收到埃及药品管理局（EDA，Egyptian Drug Authority）签发的《生物制品上市许可证》， 标志着该疫苗获得了埃及的上市许可。 ...

Core Viewpoint - The article discusses the ongoing price war in China's vaccine industry, driven by changes in supply and demand dynamics, leading to significant price reductions and financial losses for companies [4][15][22]. Group 1: Price War Dynamics - The price of a three-valent flu vaccine has dropped to 5.5 yuan, cheaper than a cup of milk tea, indicating a severe price competition in the vaccine market [5][11]. - The China Vaccine Industry Association has issued an initiative to combat "involution-style" competition, urging members to avoid bidding below cost and threatening penalties for violations [6][8][10]. - The price war has persisted for two years, with the association's initiative being the first formal stance against low-price competition, although it may not resolve the underlying issue of overcapacity [6][10][22]. Group 2: Supply and Demand Changes - The supply side is characterized by homogenization and overcapacity, with many companies entering the vaccine market, leading to intense competition and price wars [16][17]. - Demand is also under pressure, with declining public trust in vaccines and a decrease in vaccination rates, particularly for flu vaccines, which averaged below 4% in China from 2020 to 2023 [17][19]. - The shift in focus from childhood vaccines to adult vaccines due to declining birth rates has intensified competition in the adult vaccine market [17][19]. Group 3: Financial Impact on Companies - The financial repercussions of the price war are evident, with vaccine companies experiencing a 60% drop in revenue and a 113% decline in net profit in the first half of 2025 [19][20]. - Major companies like Zhifei Biological and Wantai Biological have reported significant losses, with Zhifei's revenue down 66.53% and net profit loss of 12.06 billion yuan [20][21]. - Despite some companies showing growth in sales, the overall trend indicates that increased revenue does not equate to increased profit due to drastic price reductions [21][22]. Group 4: Future Outlook and Strategies - Experts suggest that the industry is in a "deep cold moment," requiring a period of consolidation and restructuring that could last five to ten years [23]. - Companies are exploring two main strategies to navigate the competitive landscape: expanding into emerging markets and focusing on differentiated products to meet unmet clinical needs [24].